24 april, 2018
AcuCort AB (AktieTorget: ACUC) today makes a correction and clarification concerning patent terms and expiry dates for the company’s granted patents for medical formulations containing glucocorticoids for self-treatment in acute situations without access to medical personnel, “Acute Glucocorticoid Therapy”.
On April 16, 2018 AcuCort announced that the company’s patent for the above invention was granted in the US (patent no 9,925,139, B2) and that the US Patent and Trademark Office (USPTO) had extended the patent term by 1,349 days in accordance with US patent law, as the patent authority had caused a delayed approval. The correct expiry date is December 30, 2028. This means that the company enjoys patent protection in the US for a year more than previously communicated.
The patent protected invention describes and covers glucocorticoids in general, which means that the protection against competition is wider and stronger than the specific composition of the company’s pharmaceutical drug Dexa ODF, which is a fast-dissolving film to be placed on the tongue. The invention has previously resulted in granted patents for AcuCort in 30 countries. AcuCort hereby clarifies that the other granted patents for the same invention expire on April 20 or 21, 2025.
For more information, please contact
Mats Lindfors, CEO, AcuCort AB, telephone: +46 70 790 58 15, firstname.lastname@example.org
Every year millions of patients across the world use medicines containing glucocorticoids, for example against allergy and viral croup. Also cancer patients suffering from nausea and vomiting in connection with chemotherapy (CINV) use this type of drug. One big disadvantage is that these drugs are not perceived to be user-friendly or require medical staff. First having to dissolve the tablets in water can be very awkward in an acute situation, for the sufferers as well as for other persons helping them. The sufferer may have difficulties swallowing, and thus a fast-dissolving film to be placed on the tongue, with the same effect as the tablet, may have a wide application area.
AcuCort develops and commercializes Dexa ODF, a fast-dissolving oral film containing the glucocorticoid dexamethasone. Dexa ODF is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting (CINV). Dexa ODF is estimated to have a short time to market as the company only has to repeat a previously successful bioequivalence study before applying for market approval in Europe. Please visit www.acucort.com.